Article Text
Therapeutics
Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis
Statistics from Altmetric.com
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 2007;357:28–38.
Clinical impact ratings GP/FP/Primary care ★★★★★★⋆ Cardiology ★★★★★★⋆ Endocrine ★★★★★★⋆ Internal medicine ★★★★★⋆⋆
METHODS
Design:
randomised controlled trial (RCT) (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes [RECORD] trial).
Allocation:
unclear allocation concealment.*
Blinding:
blinded (outcome assessors).*
Follow-up period:
mean 3.75 …
Footnotes
-
Source of funding: GlaxoSmithKline.